NCT00502593View on ClinicalTrials.gov

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

July 23, 2007

Primary Completion Date

December 4, 2009

Study Completion Date

December 4, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemic Influenza Vaccine (GSK1562902A)

2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.

BIOLOGICAL

Fluarix™

2 doses, intramuscular injection on Days 0 and 21.

Trial Locations (7)

17300

GSK Investigational Site, Blanes (Girona)

46008

GSK Investigational Site, Valencia

46011

GSK Investigational Site, Valencia

46024

GSK Investigational Site, Valencia

46183

GSK Investigational Site, L'Eliana, Valencia

46200

GSK Investigational Site, Paiporta, Valencia

46930

GSK Investigational Site, Quart de Poblet, Valencia

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY